tradingkey.logo

TELA Bio Inc

TELA
查看详细走势图
1.130USD
-0.010-0.88%
收盘 12/19, 16:00美东报价延迟15分钟
45.59M总市值
亏损市盈率 TTM

TELA Bio Inc

1.130
-0.010-0.88%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.88%

5天

-1.74%

1月

+6.60%

6月

-31.52%

今年开始到现在

-62.58%

1年

-60.35%

查看详细走势图

TradingKey TELA Bio Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

TELA Bio Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名98/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价3.45。中期看,股价处于下降通道。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

TELA Bio Inc评分

相关信息

行业排名
98 / 208
全市场排名
228 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 5 位分析师
买入
评级
3.450
目标均价
+205.31%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

TELA Bio Inc亮点

亮点风险
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
业绩高增长
公司营业收入稳步增长,连续3年增长67.32%
业绩增长期
公司处于发展阶段,最新年度总收入69.30M美元
估值高估
公司最新PE估值-1.38,处于3年历史高位
机构减仓
最新机构持股28.74M股,环比减少25.58%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值1.80M

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

TELA Bio Inc简介

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
公司代码TELA
公司TELA Bio Inc
CEOKoblish (Antony)
网址https://www.telabio.com/

常见问题

TELA Bio Inc(TELA)的当前股价是多少?

TELA Bio Inc(TELA)的当前股价是 1.130。

TELA Bio Inc的股票代码是什么?

TELA Bio Inc的股票代码是TELA。

TELA Bio Inc股票的52周最高点是多少?

TELA Bio Inc股票的52周最高点是3.099。

TELA Bio Inc股票的52周最低点是多少?

TELA Bio Inc股票的52周最低点是0.865。

TELA Bio Inc的市值是多少?

TELA Bio Inc的市值是45.59M。

TELA Bio Inc的净利润是多少?

TELA Bio Inc的净利润为-37.84M。

现在TELA Bio Inc(TELA)的股票是买入、持有还是卖出?

根据分析师评级,TELA Bio Inc(TELA)的总体评级为买入,目标价格为3.450。

TELA Bio Inc(TELA)股票的每股收益(EPS TTM)是多少

TELA Bio Inc(TELA)股票的每股收益(EPS TTM)是-0.822。
KeyAI